Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Otis Worldwide Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.5 (market cap $8.04B), while Otis Worldwide Corp trades at $72.61 (market cap $27.84B). The key difference: Otis Worldwide Corp is far larger — about 3.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Otis Worldwide Corp pays a 2.34% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | OTIS | |
|---|---|---|
Market Cap | $8.04B | $27.84B |
Sector | Health | Industrials |
52-Week High | $339.75 | $101.07 |
52-Week Low | $241.71 | $69.34 |
Enterprise Value | $7.85B | $35.23B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Otis Worldwide trades at $73.42, up 0.45% today, with a bullish technical signal from moving averages but mixed quarterly earnings. The company maintains stable revenue near $14.4B (2025) and a net margin of 10.11%, supported by service growth and modernization initiatives like recent upgrades at Christ the Redeemer in Brazil. Cash flow from operations remains strong at $1.6B, though net cash flow turned negative in 2025 due to financing activities.
The stock offers 24% upside to the consensus price target of $91.00, with analysts divided (38% Buy, 54% Hold). Risks include debt levels (75.54% debt-to-asset ratio) and margin pressure from tariffs, but dividend growth (5% increase to $0.44) and buybacks provide shareholder value. Near-term performance hinges on Q2 2026 earnings due July 22, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
